Drug Interactions
Lecture Learning Outcomes
By the end of this lecture, students will be able to:
• Define drug interactions
• Distinguish the terms object drug and precipitant drug in drug-drug interactions
• Classify drug interactions as pharmaceutical, pharmacokinetic, or pharmacodynamic.
• Explain representative chemical and biological mechanisms that underlie drug interactions
• Predict the clinical consequence of selected common drug interactions.
• Apply a practical approach to preventing and managing drug interactions.
2. What Is a Drug Interaction?
A drug interaction occurs when one substance changes the concentration or effect of another drug.
Drug–drug interactions (DDIs): Clinically meaningful alterations in the effects of drugs administered together.
Term | Meaning |
|---|---|
Object drug / victim drug | Drug whose concentration or effect changes |
Precipitant / perpetrator | Drug, food, beverage, or supplement causing the change |
A medical condition can also alter a drug’s concentration or the patient’s response to it.
. Three Categories of Drug Interactions
Category | What changes? | Example |
|---|---|---|
Pharmaceutical | Drugs interact before administration | Incompatibility when drugs mix in an IV line |
Pharmacokinetic: PK | Drug concentration changes through ADME | Rifampin lowers warfarin exposure |
Pharmacodynamic: PD | Drug effects interact at the target, cell, or tissue level | Opioids plus alcohol increase CNS depression |
Key distinction:
PK interaction: Changes drug exposure.
PD interaction: Changes drug effects without necessarily changing concentration.
4. When Do Interactions Matter?
An interaction is clinically important when it changes the patient’s benefit or risk from treatment.
Harmful interactions
May cause:
Increased toxicity
Reduced efficacy
Treatment failure
Risk is especially important with:
Narrow-therapeutic-index drugs
Polypharmacy: Use of multiple medications
Impaired kidney function
Impaired liver function
Beneficial interactions
Some interactions are intentional.
Combination therapy may:
Increase therapeutic benefit.
Reduce adverse effects.
Produce useful synergy.
Pharmacokinetic Interactions
5. PK Interactions and ADME
The precipitant drug changes the absorption, distribution, metabolism, or excretion of the object drug.
ADME step | How an interaction might change drug exposure |
|---|---|
Absorption | Changes the amount or rate of drug reaching systemic circulation |
Distribution | Changes free-drug concentration or tissue exposure |
Metabolism | Inhibits or induces Enzymatic drug clearance or activation |
Excretion | Changes Renal, biliary, or transporter-mediated elimination |
6. Mechanisms That Alter Absorption
The lecture identifies four major mechanisms:
Changes in GI pH
Changes in GI motility
Ionic interactions or complexation
Changes in drug transporter activity
7. GI pH and Drug Ionization
Many drugs are weak organic acids or bases that exist in ionized and un-ionized forms in an aqueous environment.
Weak acids
\[ AH \rightleftharpoons A^- + H^+ \]
AH: Un-ionized form
A⁻: Ionized form
Weak bases
\[ B + H^+ \rightleftharpoons BH^+ \]
B: Un-ionized form
BH⁺: Ionized form
Why ionization matters
The un-ionized form which is more lipophilic generally crosses lipid membranes more readily across cell membranes.
In an acidic environment: Low pH
More H⁺ is present.
Drug type | Equilibrium change | Effect on passive membrane crossing |
|---|---|---|
Weak acid | More un-ionized AH | More favorable |
Weak base | More ionized BH⁺ | Less favorable |
When pH increases
Weak acids become more ionized.
Weak bases become less ionized.
The slide therefore states that alkalinizing drugs, such as antacids, may:
Decrease absorption of weak acids.
Facilitate absorption of weak bases.
8. GI Motility and Gastric Emptying
Gastric emptying determines how quickly an oral drug reaches the small intestine.
The small intestine is the main absorption site for most drugs.
A precipitant drug that changes GI motility can change the rate of absorption.
Metoclopramide + acetaminophen
Metoclopramide:
Prokinetic antiemetic.
Increases gastric emptying.
Interaction:
Faster delivery of acetaminophen to the small intestine → faster absorption → earlier onset.
Role | Drug |
|---|---|
Object | Acetaminophen |
Precipitant | Metoclopramide |
Methadone + oral drugs
Methadone:
Fully synthetic opioid receptor full agonist.
Decreases GI motility.
Delays gastric emptying.
Consequence: May delay or alter absorption of coadministered oral drugs.
Key point: Changing absorption rate does not always change total exposure.
Although the slide title says “distribution,” these examples describe absorption.
9. Ionic Interactions and Complexation
Some substances bind drugs in the GI lumen, leaving less drug available for absorption.
A. Metal-ion chelation
Tetracyclines and fluoroquinolones, including ciprofloxacin, can form poorly absorbed complexes with:
Calcium
Magnesium
Aluminum
Iron
Zinc
Common precipitants:
Antacids
Mineral supplements
Multivitamins
Result:
Complex formation → decreased antibiotic absorption → possible treatment failure.
Ciprofloxacin timing example
The lecture specifies administering ciprofloxacin:
At least 2 hours before, or
At least 6 hours after
10. Protein Binding: Free Drug Matters
The unbound drug fraction is available to:
Cross membranes
Bind targets
Undergo clearance
Protein-binding displacement
A second drug can displace a highly protein-bound drug from albumin.
Displacement → transient increase in free-drug concentration.
However, the extra free drug may also:
Distribute into tissues more rapidly.
Be cleared more rapidly.
Therefore, displacement alone rarely causes a sustained interaction.
NSAID examples
The slide describes NSAIDs as highly albumin-bound, often greater than 95%.
NSAIDs can displace drugs such as:
Warfarin
Methotrexate
in laboratory studies.
More important clinical mechanisms
Combination | Major concern |
|---|---|
NSAID + methotrexate | Reduced renal clearance → increased methotrexate toxicity |
NSAID + warfarin | Additive effects on bleeding through different mechanisms |
NSAIDs and renal perfusion
NSAID inhibits prostaglandin synthesis → afferent arteriolar constriction → reduced renal blood flow and GFR → potentially reduced methotrexate clearance.
Concern increases when displacement occurs alongside other PK/PD interactions or involves a narrow-therapeutic-index drug.
11. Altered Drug Metabolism
The major enzyme family discussed is cytochrome P450: CYP.
Inhibition versus induction
Change | Typical effect | Typical onset |
|---|---|---|
Enzyme inhibition | Increased parent-drug exposure; decreased formation of an active metabolite | Often hours to a few days |
Enzyme induction | Decreased parent-drug exposure; increased metabolite formation | Usually days to weeks |
The clinical result depends on whether the parent drug, metabolite, or both are active or toxic.
Common CYP examples
Enzyme | Examples mentioned |
|---|---|
CYP3A4 | Common pathway in drug interactions |
CYP2D6 | Metoprolol, codeine |
CYP2C9 | Warfarin, some NSAIDs |
CYP2C19 | Omeprazole, diazepam |
12. CYP Inhibition Examples
A. Amiodarone + warfarin
Object: Warfarin
Precipitant: Amiodarone
Mechanism: CYP2C9 inhibition
Sequence:
Less warfarin metabolism → increased warfarin exposure → increased bleeding risk.
B. Paroxetine + codeine
Object: Codeine
Precipitant: Paroxetine, an SSRI antidepressant
Mechanism: CYP2D6 inhibition
Normally:
\[ \text{Codeine}\xrightarrow{\text{CYP2D6}}\text{Morphine} \]
With inhibition:
Less morphine formation → reduced analgesia.
Important: Enzyme inhibition can reduce efficacy when metabolism is needed for drug activation.
C. Grapefruit + susceptible oral CYP3A substrates
Object: A susceptible oral CYP3A substrate
Precipitant: Grapefruit products
Mechanism: Inhibition of intestinal CYP3A4
The slide identifies furanocoumarins as compounds responsible for this inhibition.
Consequence: Higher oral drug exposure and increased toxicity risk.
13. CYP Induction Examples
Induction increases enzyme expression or activity and can lower concentrations of susceptible parent drugs.
A. Rifampin + warfarin
Rifampin:
Antibiotic used for tuberculosis.
Strong inducer of:
CYP3A4
CYP2C9
CYP2C19
P-gp
Consequence: Lower warfarin exposure → reduced anticoagulation.
B. St. John’s wort + susceptible drugs
St. John’s wort:
Herbal product used for depression.
Induces CYP3A4 and P-gp.
Consequence: Can lower exposure to susceptible drugs, including oral contraceptives, reducing effectiveness.
C. Chronic heavy alcohol use + acetaminophen
Chronic heavy alcohol exposure can increase CYP2E1 activity, partly through protein stabilization.
\[ \text{Acetaminophen}\xrightarrow{\text{CYP2E1}}\text{NAPQI} \]
NAPQI: Hepatotoxic acetaminophen metabolite.
Potential consequence: Increased formation of the toxic metabolite.
Enzyme–transporter overlap
The same precipitant can induce both CYP enzymes and MDR1/P-gp.
Therefore, one substance may affect both metabolism and transport.
14. Transporter-Mediated Interactions
Changes in transporter activity can alter:
Absorption
Tissue distribution
Excretion
Transporter | Typical location | Effect of inhibition |
|---|---|---|
P-gp/ABCB1 and BCRP/ABCG2 | Intestine, liver, kidney, blood–brain barrier | May increase absorption, systemic exposure, or tissue exposure |
OAT and OCT | Renal proximal tubule | Can reduce active secretion and increase drug exposure |
OATP | Liver and intestine | Can reduce hepatic uptake or alter intestinal absorption |
Location matters: Inhibiting intestinal efflux, hepatic uptake, or renal secretion affects different steps in the drug’s path.
15. Quinidine + Digoxin
Digoxin
Cardiac glycoside.
Positive inotrope: Increases contractile force.
Inhibits cardiac Na⁺/K⁺-ATPase.
Has a narrow therapeutic index.
Not significantly metabolized by CYP enzymes.
Eliminated mainly unchanged through the kidneys; P-gp contributes to its transport and elimination.
Quinidine
Class IA antiarrhythmic.
Inhibits P-gp.
Also strongly inhibits CYP2D6.
Interaction mechanism
Normal P-gp:
Limits digoxin absorption.
Contributes to digoxin elimination.
Quinidine inhibits P-gp → less digoxin efflux → increased plasma digoxin concentration → increased toxicity risk.
Risk is greater with impaired renal function.
Role | Drug |
|---|---|
Object | Digoxin |
Precipitant | Quinidine |
Main mechanism here | P-gp inhibition |
Exam distinction: Quinidine inhibits CYP2D6, but the digoxin interaction is primarily a transporter interaction, not a CYP interaction.
Other P-gp inhibitors listed
Cyclosporine
Erythromycin
Verapamil
Curcumin
Lapatinib
Transporter interactions may affect several organs simultaneously.
16. NSAIDs + Methotrexate
Major concern: Reduced renal elimination, rather than protein displacement alone.
NSAID effect | Consequence for methotrexate |
|---|---|
Inhibits renal prostaglandin synthesis | May reduce renal perfusion and glomerular filtration |
Competes with renal organic anion transport | May reduce active tubular secretion |
Net effect | Methotrexate accumulation and increased toxicity risk |
NSAIDs shown:
Aspirin
Naproxen
Ibuprofen
Methotrexate:
Antifolate drug used in chemotherapy and other conditions.
Generally not considered a major MDR1/P-gp substrate.
Key point: Its transporter-related interaction here involves renal OAT transport, not primarily P-gp.
17. One Object Drug Can Have Multiple Interaction Sites
Atorvastatin example
Atorvastatin is handled by:
CYP3A4
P-gp
OATP transporters
Different precipitants can affect different parts of its disposition.
Precipitant | Mechanisms listed | Increase in atorvastatin plasma concentration shown |
|---|---|---|
Cyclosporine | P-gp inhibition; OATP1B1 inhibition; weak CYP3A inhibition | 8.7-fold |
Clarithromycin | P-gp inhibition; strong CYP3A inhibition | 4.4-fold |
Diltiazem | P-gp inhibition; moderate CYP3A inhibition | 51% |
Gemfibrozil | OATP1B1 inhibition | 35% |
These values are the examples presented in the lecture.
Drug classes
Cyclosporine: Immunosuppressant
Clarithromycin: Antibiotic
Diltiazem: Calcium channel blocker
Gemfibrozil: Lipid-lowering drug
Question to ask: Where does the object drug travel, and which enzymes or transporters control each step?
Pharmacodynamic Interactions
18. Definition and Types
A pharmacodynamic interaction occurs when the precipitant changes the object drug’s activity at its site of action.
Drug concentrations may remain unchanged while effects:
Add together
Become greater than expected
Oppose one another
Create a new toxicity risk
Let E represent effect.
Type | Relationship | Meaning | Example |
|---|---|---|---|
Additive / summation | \(E_{A+B}=E_A+E_B\) | Combined effect equals the sum | Acetaminophen + ibuprofen for analgesia |
Synergistic / potentiation | \(E_{A+B}>E_A+E_B\) | Combined effect exceeds the expected sum | Trimethoprim + sulfamethoxazole |
Antagonistic | \(E_{A+B}<E_A+E_B\) | One drug reduces the other’s effect | Metoprolol reduces dobutamine’s effect |
19. Therapeutic Synergy: Trimethoprim + Sulfamethoxazole
These drugs inhibit different steps in the same bacterial folate pathway.
The lecture uses urinary tract infection treatment as an example.
Terms
PABA: Para-aminobenzoic acid
DHF: Dihydrofolate
THF: Tetrahydrofolate
Sequential blockade
Drug | Target/action | Result |
|---|---|---|
Sulfamethoxazole | Competes with PABA at dihydropteroate synthase | Less downstream DHF formation |
Trimethoprim | Inhibits dihydrofolate reductase: DHFR | Less conversion of DHF to THF |
Block an earlier step + block a later step → synergistic inhibition of bacterial THF synthesis.
The slide also mentions sulfonamides such as sulfadiazine; the main combination illustrated is trimethoprim–sulfamethoxazole.
Selective toxicity
Sulfamethoxazole:
Humans do not synthesize folate from PABA.
Humans lack dihydropteroate synthase.
Trimethoprim:
Inhibits bacterial DHFR much more strongly than human DHFR.
20. Types of Antagonistic Interactions
A. Pharmacologic antagonism
Drugs act at the same receptor system.
Example:
Dobutamine: β₁ agonist.
Metoprolol: β₁ antagonist.
Metoprolol reduces dobutamine’s β₁-mediated effects.
B. Physiologic / functional antagonism
Drugs produce opposing physiological effects through different mechanisms.
Example:
Phenylephrine: α₁ agonist and vasopressor → raises blood pressure.
Nitroprusside: Vasodilator → lowers blood pressure.
C. Chemical antagonism
One drug directly binds or neutralizes another.
Example:
Protamine sulfate: Highly basic peptide drug.
Binds heparin and reverses its anticoagulant effect.
Type | Main idea |
|---|---|
Pharmacologic | Opposing actions within the same receptor system |
Physiologic | Opposing physiological effects |
Chemical | Direct binding/neutralization |
Antagonism may be harmful or intentional, such as reversal of anticoagulation.
21. PD Interactions That Increase Toxicity
Combination | Major risk | Why? |
|---|---|---|
Anticoagulant + antiplatelet drug or NSAID | Bleeding | Multiple effects impair hemostasis or damage GI mucosa |
Opioid, benzodiazepine, or alcohol combinations | Sedation and respiratory depression | Combined CNS depression |
NSAID + corticosteroid | GI ulceration or bleeding | Combined impairment of GI protective mechanisms |
CNS depressants and GABA-A
The lecture discusses:
Ethanol
Barbiturates, including phenobarbital
Benzodiazepines
These depress CNS activity and can enhance inhibitory GABA-A signaling.
Combined effects may be:
Additive, or
More than additive: Synergistic
GABA: Gamma-aminobutyric acid.
The receptor diagram shows distinct interaction sites for alcohol, barbiturates, and benzodiazepines.
Opioids also cause CNS and respiratory depression, but act primarily through opioid receptors rather than the GABA-A sites shown.
22. Practical Approach to Interactions
Learning objective application
For any interaction, work through:
Identify the object drug.
Which drug’s exposure or effect changes?
Identify the precipitant.
Include prescription drugs, OTC products, supplements, foods, and beverages.
Classify the interaction.
Pharmaceutical, PK, or PD?
Identify the mechanism.
Absorption, enzymes, transporters, receptor effects, or chemical binding?
Predict the consequence.
Higher exposure, lower exposure, reduced activation, additive toxicity, or antagonism?
Consider patient risk.
Narrow therapeutic index, kidney/liver impairment, and polypharmacy.
Match prevention and monitoring to the mechanism.
Check compatibility before mixing drugs.
Separate administration when GI binding is the mechanism.
Consider an alternative combination or an appropriate dose adjustment.
Monitor relevant drug concentrations, clinical response, or toxicity.
23. Common Interaction Examples to Know
Combination | Main mechanism | Predicted consequence |
|---|---|---|
Metoclopramide + acetaminophen | Increased gastric emptying | Faster absorption and earlier onset |
Multivalent cations + ciprofloxacin | Chelation | Reduced antibiotic absorption |
Cholestyramine + levothyroxine/warfarin | GI binding | Reduced absorption |
Amiodarone + warfarin | CYP2C9 inhibition | Increased warfarin exposure and bleeding risk |
Paroxetine + codeine | CYP2D6 inhibition | Less morphine formation and reduced analgesia |
Grapefruit + susceptible oral CYP3A substrate | Intestinal CYP3A4 inhibition | Increased drug exposure |
Rifampin + warfarin | Enzyme induction | Reduced warfarin exposure and anticoagulation |
St. John’s wort + susceptible oral contraceptive | CYP3A4/P-gp induction | Reduced exposure and effectiveness |
Chronic heavy alcohol use + acetaminophen | Increased CYP2E1 activity | Potentially increased NAPQI formation |
Quinidine + digoxin | P-gp inhibition | Increased digoxin exposure and toxicity risk |
NSAID + methotrexate | Reduced renal clearance | Methotrexate accumulation |
Metoprolol + dobutamine | Pharmacologic antagonism | Reduced dobutamine effect |
Protamine + heparin | Chemical antagonism | Reversal of heparin anticoagulation |
Opioid + benzodiazepine/alcohol | Combined CNS depression | Sedation and respiratory depression |
24. Take-Home Points
Pharmaceutical interactions: Occur before administration.
PK interactions: Change exposure through ADME, often involving enzymes or transporters.
PD interactions: Change effects without necessarily changing drug concentration.
Enzyme inhibition can increase toxicity or reduce activation and efficacy.
Protein displacement alone rarely explains a sustained interaction.
A single drug can be affected by several enzymes, transporters, and precipitants.
Good interaction assessment connects mechanism → patient risk → expected consequence → monitoring plan.